Bora Pharmaceuticals Announces Plans to Acquire Rockville-Based MacroGenics
Last week, Taiwan-based Bora Pharmaceuticals announced plans to acquire the Good Manufacturing Practices (GMP) operations of Rockville-based MacroGenics in a deal valued at $122.5 million, with an additional contingent payment of up to $5 million tied to future customer orders. The acquisition includes MacroGenics’ biologics manufacturing facility in Rockville, as well as a warehousing center in Frederick. Through this acquisition, Bora plans to integrate the Rockville facility into its growing biologics CDMO platform, expanding its U.S. manufacturing capabilities, and increasing total biologics drug substance capacity to 20,000 liters. The site already supports commercial-stage monoclonal antibody programs and clinical manufacturing operations and includes FDA-inspected facilities with advanced bioreactor capacity. Approximately 140 employees are expected to transition to Bora following the transaction.
The deal is significant not only for the companies involved, but also for Montgomery County’s position as the 3rd largest biopharma hubs in the nation and signals continued confidence in the County’s highly skilled workforce—where 1 in 3 adults aged 25 or older hold an advanced degree—existing infrastructure, and established life sciences ecosystem. The County is home to a dense network of life sciences companies, federal agencies including the FDA, NIST, and NIH, and research institutions that make it uniquely positioned to support life sciences companies in all stages of growth.
This also marks the second major CDMO and biomanufacturing announcement in Montgomery County in recent months. In March, Sout Korea’s largest biotech company, Samsung Biologics, opened its first U.S. manufacturing facility through the acquisition of the former GSK campus in Rockville, further underscoring the County’s growing prominence as a destination for global biomanufacturing investment. The $353 million acquisition retained more than 500 local jobs and brings an additional 60,000 liters of drug substance capacity to the company’s operations.
As demand for biologics manufacturing capacity continues to grow globally, Montgomery County remains well-positioned to become an anchor for companies from around the world looking to establish life sciences advanced manufacturing operations in the U.S.
